A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.
An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.